Skip to content

Efficacy of neurofeedback-assisted meditation using wearable device on stress reduction: A Randomized, Double-blind and Controlled Study

Efficacy of neurofeedback-assisted meditation using wearable device on stress reduction: A Randomized, Double-blind and Controlled Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0007413
Enrollment
80
Registered
2022-06-17
Start date
2021-05-18
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Participants were asked to perform meditation using the device twice a day for a total of 2 weeks, 14days, for 12minutes per session. The measured bio-signals are linked to the Applic

Sponsors

Seoul National University Bundang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: All participants were between 19 and 65 years old with psychological stress and subclinical symptoms of depression or anxiety. Enrolled participants underwent screening tests at the first visit, and we included those who met both of the following criteria: (1) Perceived Stress Scale (PSS) score = 14; and (2) either Beck Depression Inventory-II (BDI-II) score = 20 or Insomnia Severity Index (ISI) score = 8.

Exclusion criteria

Exclusion criteria: Exclusion criteria were as follows: (1) psychiatric disorders including mood disorders, anxiety disorders, and psychotic disorders; (2) any other sleep disorders such as insomnia disorder, sleep apnea or restless legs syndrome based on the diagnostic criteria of DSM-5 or International Classification of Sleep Disorders (ICSD)-3; (3) medical illness such as cerebrovascular disease, heart disease, malignancy, lung disease, endocrine disorders, infectious diseases and impaired renal or hepatic function; (4) a history of neurological abnormalities such as head trauma or convulsive disease; (5) those with chronic pain; (6) those who are pregnant, lactating, or planning to become pregnant during this study; (7) those who have received cognitive behavioral therapy, biofeedback, neurofeedback, or meditation therapy within 1 year; (8) those who have taken steroids or hormone therapy (corticosteroids, oral contraceptives, sex hormone injections) within the last 4 weeks (9) any acute severe stressful life events (death of family members/ divorce/ separation/ debt/ run away/ business failure/ serious illness/ marriage, etc) within four weeks prior to study; (10) use of any psychiatric drugs such as sleeping pills, antidepressants, anxiolytics, and stimulants within 4 weeks prior to study; (11) shift work of jet lag within 2 weeks prior to study.

Design outcomes

Primary

MeasureTime frame
K-BDI-II(Korea Beck Depression Inventory), PSS (Percieved Stress Scale)

Secondary

MeasureTime frame
qEEG(quantitative electroencephalography), HRV(Heart Rate Variability), serum cortisol, ACTH(adrenocorticotrophic hormone), IL-6(Interleukin-6), TNF-a(Tumor Necrosis Factor-alpha), ISI(Insomnia Severity Index), PSQI(Pittsburgh Sleep Quality Index), STAI(State Trait Anxiety Inventory), QOL BREF(WHO Quality of Life Scale abbreviateed version)

Countries

Korea, Republic of

Contacts

Public ContactEunyoung Lee

VHS Medical Center

ehddbs48@naver.com+82-2-2225-4391

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 7, 2026